Capecitabine Tablet, Film Coated
Product Images NDC 68001-644

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Capecitabine (NDC 68001-644). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bluepoint Laboratories, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label- Capecitabine Tablets Usp 150 mg (Capecitabine150mglabel)

Label for Capecitabine Tablets, USP 150 mg, film coated, oral dosage form. The bottle label indicates 60 tablets per container, manufactured by Hetero Labs Limited for BluePoint Laboratories. The label includes storage instructions, a warning that it is a hazardous cytotoxic drug, and a U.S. contact number. The label has a barcode and a revision date of 12/2024.*

FDA Label Image

Label- Capecitabine Tablets Usp 500 mg (Capecitabine500mglabel)

Label for Capecitabine Tablets USP 500 mg film-coated tablets, oral use, containing 120 tablets. Manufactured by Hetero Labs Limited for BluePoint Laboratories. The label includes instructions to swallow tablets whole with water within 30 minutes of a meal, warnings about the drug's hazardous nature, and storage conditions of 20°C to 25°C. It features a barcode and contact information for customers.*

FDA Label Image

Capecitabinechemicalstructure (Capecitabinechemicalstructure)

Chemical structure of Capecitabine, showing its molecular configuration with various functional groups including a fluorine atom, amide groups, and a sugar moiety with hydroxyl groups.*

FDA Label Image

Capecitabinefigure1 (Capecitabinefigure1)

A survival curve chart comparing the treatment groups of Capecitabine and 5-FU plus Leucovorin over months since randomization. The graph shows survival probability on the y-axis and time in months on the x-axis, with corresponding patient numbers at risk displayed below the x-axis for both groups.*

FDA Label Image

Capecitabinefigure2 (Capecitabinefigure2)

A survival curve chart comparing two treatment groups: 5-FU plus Leucovorin and Capecitabine, with survival probability on the vertical axis and months since randomization on the horizontal axis. The chart includes numbers at risk for each group at various time points up to 96 months.*

FDA Label Image

Capecitabinefigure3 (Capecitabinefigure3)

A survival curve chart displaying estimated probability versus time in days, comparing two treatment groups: a 5-FU plus Leucovorin (Mayo Regimen) group and a Capecitabine 1250 mg per square meter twice daily intermittent group. The chart shows declining survival probabilities over approximately 1500 days with a reference marker around 391-392 days.*

FDA Label Image

Capecitabinefigure4 (Capecitabinefigure4)

A survival curve chart depicting estimated probability over time (days) comparing two treatment groups: Docetaxel 100 mg/sqm every 3 weeks (dashed line) and Capecitabine 1250 mg/sqm twice daily intermittently with Docetaxel 75 mg/sqm every 3 weeks (solid line). The x-axis represents time in days up to 800, and the y-axis represents estimated probability from 0 to 1. Two vertical arrows mark specific time points at approximately 128 and 186 days.*

FDA Label Image

Capecitabinefigure5 (Capecitabinefigure5)

A Kaplan-Meier survival curve comparing two treatment groups over time in days. One group is treated with Docetaxel 100 mg/sqm every 3 weeks, and the other with Capecitabine 1250 mg/sqm twice daily intermittently combined with Docetaxel 75 mg/sqm every 3 weeks. The Y-axis shows estimated probability, ranging from 0 to 1.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.